Lifecore Biomedical Inc LFCR.OQ LFCR.O is expected to show a rise in quarterly revenue when it reports results on November 6 for the period ending August 31 2025
The Chaska Minnesota-based company is expected to report a 7.1% increase in revenue to $26.471 million from $24.71 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Lifecore Biomedical Inc is for a loss of 31 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Lifecore Biomedical Inc is $8.75, about 18.7% above its last closing price of $7.11
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
May. 31 2025 | -0.09 | -0.06 | Beat | 36.8 | |
Feb. 28 2025 | -0.15 | -0.15 | -0.47 | Missed | -213.3 |
Nov. 30 2024 | -0.34 | -0.29 | -0.25 | Beat | 13.8 |
Aug. 31 2024 | -0.47 | -0.46 | -0.49 | Missed | -5.4 |
May. 31 2024 | -0.12 | -0.12 | -0.17 | Missed | -41.7 |
Feb. 29 2024 | -0.06 | | |||
Nov. 30 2023 | -0.07 | ||||
Aug. 31 2023 | -0.26 |
This summary was machine generated November 4 at 22:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)